About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

NCT01227577·32 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novartis Pharmaceuticals

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients with Ph+ CML-CP within 3 months of diagnosis. Male or female patients' ≥ 18 years of age. Patients must have adequate end organ function.

You may not be if

Impaired cardiac function as defined by the protocol. Patients with contraindications to receiving nilotinib, including concomitant medications.

The record

StatusCompleted

PhasePhase 4

Taking part128

StartedNov 2010

UpdatedFeb 8, 2016

Conditions

Chronic Myelogenous Leukemia in Chronic Phase

Where32

Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
Burbank, California, United States
Bay Area Cancer Research Dept.ofBayAreaCancerResearch
Concord, California, United States

Clareo Health | CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib